key: cord-0920066-sy9ox5mt
authors: Hryniewicki, Adam T.; Tolia, Vaishal M.; Nene, Rahul V.
title: Case Report: Cardiac Tamponade following COVID-19 Vaccination
date: 2021-10-23
journal: J Emerg Med
DOI: 10.1016/j.jemermed.2021.10.008
sha: edad1077d1e3ac19efc5065b821ff60bcb5a8669
doc_id: 920066
cord_uid: sy9ox5mt

Background Acute pericarditis is a diffuse inflammation of the pericardial sac with many well-defined etiologies. Acute pericarditis as a vaccine-related adverse event is a rare entity and the association between pericarditis and the immunogenic response to COVID-19 vaccines is still being fully characterized. Case Report A previously healthy 18-year-old male presented with fever, pleuritic chest pain, and shortness of breath shortly after receiving the first dose of a COVID-19 mRNA-based vaccine. The patient was found to have a large pericardial effusion with early tamponade physiology requiring pericardiocentesis. Why Should an Emergency Physician Be Aware of This: As COVID-19 vaccination becomes more prevalent globally, physicians should be aware of pericarditis as a rare but potentially serious adverse reaction.

Since April 2021, the CDC has seen an increase in the incidence of pericarditis and myocarditis following vaccination with the mRNA-based vaccines from Pfizer-BioNTech and Moderna, particularly in adolescents and young adults. Acute pericarditis is a diffuse inflammation of the pericardial sac with many well-defined etiologies. Acute pericarditis as a vaccine-related adverse event is a rare entity and the association between pericarditis and the immunogenic response to coronavirus disease 2019 (COVID-19) vaccines is still being fully characterized. Here, we present a case of a previously healthy 18-

year-old male who presented with fever and pleuritic chest pain after receiving the first dose of a COVID-19 mRNA-based vaccine. The patient was found to have acute pericarditis and developed a large pericardial effusion with early tamponade physiology and required emergent pericardiocentesis.

A previously healthy 18-year-old male presented with a chief complaint of fever, pleuritic chest pain, and shortness of breath three weeks after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine. On arrival to the emergency department (ED), vital signs were remarkable for a temperature of 100.3 F and heart rate of 111 beats per minute. The patient had an unremarkable physical exam other than regular tachycardia. ECG demonstrated diffuse ST elevations and PR depressions (Figure 1 ), concerning for acute pericarditis. Chest X-ray, formal echocardiogram, and troponins were all within normal limits. Following discussion with the cardiology service, he was discharged on a regimen of ibuprofen 800 mg every eight hours, with a plan to follow-up with cardiology as an outpatient. Three days later, his chest pain was persistent, and he was started on additional colchicine 0.6 mg daily.

Approximately ten days later, the patient returned to the ED with ongoing fever, pleuritic chest pain, shortness of breath, and dizziness. Vital signs were remarkable for an elevated temperature to 100.1 F, tachycardia to 120 beats per minute, and tachypnea to 31 breaths per minute. Blood pressure was normal. ECG demonstrated persistent diffuse ST elevations. Chest X-ray now showed an enlarged cardiac silhouette ( Figure 2 ). Echocardiogram demonstrated a large pericardial effusion with evidence of early tamponade, including a dilated inferior vena cava (IVC) and right atrial diastolic collapse ( Figure 3 ).

The patient was admitted to the cardiac intensive care unit and underwent emergent pericardiocentesis with removal of approximately 600 mL of serosanguinous fluid. Pericardial fluid studies were consistent with an exudative process. The patient was discharged four days later on indomethecin 25 mg every six hours and colchicine 0.6 mg every 12 hours. He was readmitted to the hospital one week later for persistent tachycardia and recurrent pericardial effusion, which improved after intravenous ketorolac and intravenous methylprednisolone. He was ultimately discharged on prednisone 40 mg daily, celecoxib 200 mg every 12 hours, and a plan to start rilonacept, an IL-1 inhibitor recently approved for the treatment of recurrent pericarditis. 1

Beginning in April 2021, there has been increasing awareness of COVID-19 vaccine-related adverse reactions, particularly pericarditis and myocarditis in younger patients. Here, we present a case of pericarditis following mRNA-based vaccination, which followed a classic constellation of symptoms including pleuritic chest pain, ECG abnormalities, history of fever, and a pericardial effusion. ECG abnormalities of pericarditis typically include diffuse concave ST elevations and PR depressions in the precordial and limb leads (I, II, III, avL, avF, V2-6) with reciprocal ST depression and PR elevation in aVR and lead I. 2, 3 The various etiologies of pericarditis can be categorized into infectious (primarily viral), non-infectious (e.g. neoplasm, trauma, metabolic), and inflammatory (e.g. immunologic, rheumatologic), though up to 86% may be idiopathic. 4, 5 Pericardial effusions may be present in up to two-thirds of pericarditis cases, although large effusions (greater than 20 mm in width) are much more rare and constitute only 3% of cases. 6 Echocardiography is necessary for patients with suspected or confirmed pericarditis, as a pericardial effusion can progress to tamponade physiology before enlarging the cardiac silhouette on chest X-ray or before the patient develops significant vital sign abnormalities.

NSAIDS remain the cornerstone of treatment (ibuprofen 600-800 mg every six to eight hours), and colchicine has been shown to reduce symptoms at 72 hours and the risk of recurrent pericarditis. 14, 15 Patients with large pericardial effusions, and clearly those with tamponade physiology, required pericardiocentesis and placement of a pericardial drain.

Pericarditis is a rare event following immunizations, however it has been described following vaccinations to influenza and smallpox. 7, 8 One study determined that the rate of inflammatory cardiac conditions -myocarditis, pericarditis, and arrhythmias -following immunization with live virus vaccines (excluding smallpox) was no greater than the background rate. 9 However, the incidence of myopericarditis following immunization with novel vaccine technologies, namely the mRNA vaccines widely adopted for the COVID-19 pandemic, has yet to be fully elucidated. A recent case series reported seven cases of myopericarditis within four days of receiving the Pfizer-BioNTech COVID-19 vaccine. 10 A recent series detailing immune-mediated disease flares following mRNA vaccination also reported two cases of pericarditis. 11 As of June 2021, the Vaccine Adverse Event Reporting System (VAERS) has documented 518 confirmed cases of myocarditis or pericarditis following mRNA-based COVID-19 vaccination in patients 30 years of age or younger. 12 Most developed symptoms within one week of vaccination, were predominantly male, and symptoms were more likely to develop following the second dose. Most required hospitalization, though recovered well with standard treatment.

While no mechanistic basis has been characterized describing the link between pericarditis and vaccination, it is suspected to be due to a high level of systemic reactogenicity and immunogenicity to the vaccine. The observation that younger patients experience more side effects following vaccination and that their neutralizing antibody titers reach higher levels than their adult counterparts supports this theory. 13 It is imperative that cases of myopericarditis following vaccination for COVID-19 be reported to VAERS. Despite our experience with this case, we agree with the Centers for Disease Control and Prevention (CDC) recommendation that the benefits outweigh the risks of vaccination and should continue to be offered to everyone who is eligible. 16 Why should an emergency physician be aware of this?

Mass vaccination is considered the cornerstone for ending the COVID-19 pandemic, and as more people and new populations are vaccinated, new adverse events are being documented. It is important for emergency physicians to be aware of the association between mRNA-based COVID-19 vaccination and myopericarditis, ensure these patients get the appropriate evaluation and treatment, and ensure these cases are reported to the appropriate public health officials. 

Approves First Treatment for Disease That Causes Recurrent Inflammation in Sac Surrounding Heart

Electrocardiographic manifestations: acute myopericarditis

Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review

Pericardial syndromes: an update after the ESC guidelines 2004

Myocarditis and pericarditis in children

Clinical practice. Acute pericarditis

Recurrence of pericarditis after influenza vaccination: a case report and review of the literature

Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination

Myocarditis and pericarditis are rare following live viral vaccinations in adults

Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel)

Selected Adverse Events Reported after COVID-19 Vaccination. cdc.gov

Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers)

Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease

ESC Guidelines on the diagnosis and management of pericardial diseases

Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial

Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination